- Vaccines can provide safe and long-lasting immunity and logistical advantages over other treatment modalities
- Integrating its precision medicine approach, AC Immune advances three clinical-stage vaccines targeting Tau, Abeta and α-synuclein
- Precisely-targeted active immunotherapy could prevent disease pathways before irreversible neuronal damage occurs
LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) — AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today welcomed Cynthia A. Lemere, leader Opinion Leader (KOL), Ph.D., from the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital and Harvard Medical School, Boston, for a webinar focusing on vaccines to treat and prevent Alzheimer’s disease and Parkinson’s.
Over 180 attendees from the investment and biopharma industries registered to attend the webinar, which included presentations from Dr. Lemere and members of the AC Immune leadership team, as well as a Q&A session . To view a replay of the event, please click here.
During the event, presenters discussed how vaccination can provide safe and long-lasting immunity and logistical advantages over other treatment modalities. A summary of this discussion is provided below:
- Vaccines stimulate antibody responses that simultaneously target multiple disease epitopes, offering potential for higher efficacy compared to agents targeting single epitopes
- Vaccines improve an individual’s immune response by allowing the immune system to optimize antibodies for a specific proteinopathy over time
- Vaccine-induced antibodies are produced by the patient’s own immune system, providing ongoing functional advantages over exogenously prepared antibodies
- Vaccines provide long-lasting immune activation and consistent antibody titers, which may improve long-term safety and efficacy compared to passive immunotherapies
- Vaccination can enable annual or semi-annual dosing regimens that improve costs and patient compliance
Dr. Lemere commented: “The ability of vaccines to safely and specifically target multiple epitopes on the toxic drivers of neurodegenerative diseases makes them uniquely suited to address unmet patient needs. Data from previous clinical studies conducted by AC Immune and others clearly demonstrate the therapeutic potential of vaccines and provide strong scientific rationale for the Company’s ongoing and planned trials. These are further supported by recent data generated with monoclonal antibodies directed against therapeutic targets such as pyroglutamate-Abeta. Additionally, the innovative designs of these trials could enable rapid demonstration of clinical proof of concept, which would represent an important step in making prevention a practical reality for those at risk.
During the webinar, AC Immune management provided an overview of AC Immune’s industry-leading portfolio of candidate vaccines to treat and prevent neurodegenerative diseases. These include:
- ACI-35.030, an anti-phospho-Tau vaccine derived from AC Immune’s SupraAntigen®-V platform and in partnership with Janssen Pharmaceuticals, Inc. -V with no safety issues, robust immunogenicity and evidence of response lasting immunity that supports a disease prevention approach. Disclosure of late-stage development plans for ACI-35.030 is expected in 2022.
- ACI-24.060, an Abeta vaccine that targets the two most toxic forms of the protein, pyroglutamate-Abeta and the oligomer Abeta. ACI-24.060 is being evaluated in the Phase 1b/2 ABATE study in patients with Alzheimer’s disease and people with Down syndrome. Interim data from the trial, which has an innovative biomarker-based design that can accelerate clinical proof-of-concept time and transition to pivotal studies, is expected in 2022.
- ACI-7104, an α-synuclein vaccine under development for the treatment of Parkinson’s disease and other α-synucleinopathies. AC Immune plans to initiate an adaptive phase 2 biomarker-based trial of ACI-7104 in patients with Parkinson’s disease in 2022.
Dr. Andrea Pfeifer, CEO of AC Immune, commented“Our clinical-stage vaccines target three key features of neurodegenerative diseases. We believe these programs, together with our cutting-edge diagnostic imaging agents, position AC Immune to lead the field in the early diagnosis and prevention of neurodegenerative diseases. We thank Dr. Lemere for his expert comments on the potential benefits that effective vaccinations can offer patients and look forward to early clinical data with our proprietary ACI-24.060 vaccine.
About the SupraAntigen® Platform
AC Immune’s clinically validated SupraAntigen® platform uses proprietary liposomes to rapidly generate novel vaccines (SupraAntigen-V) for active immunization as well as best-in-class monoclonal antibodies (SupraAntigen-A) for passive immunization against key targets neurodegenerative diseases. Antibodies generated by the platform are highly specific for pathological conformations of misfolded proteins and have shown strong safety. The SupraAntigen® platform has successfully generated two candidate vaccines and antibodies that have been validated in clinical studies and has led to multiple global partnerships with world-renowned pharmaceutical companies. In addition to targeting Abeta and Tau, AC Immune generated conformation-specific antibodies against emerging neurodegenerative disease targets, including alpha-synuclein, TDP-43, and the NLRP3 inflammasome pathway.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its large and diverse portfolio of first-class and first-class assets, which currently includes ten therapeutic candidates and three diagnostic candidates, six of which are currently in phase 2 clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, including Roche Group member Genentech, Eli Lilly and Company and Janssen Pharmaceuticals, Inc., which has resulted in securing unrestricted funding. substantial dilution to advance its proprietary programs. and > $3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU and SG. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, NO and RU.
For more information, please contact:
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than statements of fact. historical records and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “could”, “shall”, “should”, “expect”, “plan”, “anticipate”, “believe”, “valued”. ,” “predicted”, “plans”, “potential”, “outlook” or “continuing” and other comparable terms. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such statements.These risks and uncertainties include those described under “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Outlook” of AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, our suppliers, our patients and employees and any other impacts of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not assume any we have no obligation to update them in light of new information, future developments or otherwise, except as required by applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.